Floatz logo

Peginterferon

Nonalcoholic Fatty Liver Disease

First Affiliated Hospital of Wenzhou Medical UniversityPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Nonalcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Exenatide
Fudan University
Phase 4BBB
Ezetimibe
Yonsei University
Phase 4BBB
pf-06865571
Pfizer
Phase 2BB
CLESACOSTAT
Columbia University
Phase 2BB
Rosuvastatin
Yonsei University
Phase 4BB

View all 23 →

Same molecule, other indications

Peginterferon is also rated in:

hepatitis C virus infectionDormant
BBB
Indicative ·
75 / 100
View asset →
Chronic Hepatitis bDormant
BB
Indicative ·
65 / 100
View asset →
Liver FibrosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →